| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
1,518,000 |
| Market
Cap: |
10.19(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.2 - $18.63 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for diseases of the eye. Co.'s two marketed products are EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Co. is also progressing its pipeline of proprietary programs targeted to address front and back of the eye diseases, including KPI-287 and glucocorticoid receptor modulators.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
11,400 |
11,400 |
3,865,837 |
| Total Sell Value |
$0 |
$76,777 |
$76,777 |
$1,938,481 |
| Total People Sold |
0 |
6 |
6 |
7 |
| Total Sell Transactions |
0 |
6 |
6 |
15 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
14,736 |
26,619 |
|
- |
|
| Perry Gregory D |
|
– • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,738 |
2,538 |
|
- |
|
| Myers C. Daniel |
|
– • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,640 |
1,640 |
|
- |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,639 |
27,134 |
|
- |
|
| Koven Andrew I |
|
– • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,197 |
3,257 |
|
- |
|
| Brazzell Kim |
SEE REMARKS |
• – – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
17,916 |
36,452 |
|
- |
|
| Rosen Howard B |
|
– • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,502 |
3,399 |
|
- |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,648 |
25,055 |
|
- |
|
| Blumenkranz Mark S. |
|
– • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,640 |
6,807 |
|
- |
|
| Farid Marjan |
|
– • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
1,600 |
|
- |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
71,715 |
117,681 |
|
- |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
6,977 |
22,407 |
|
- |
|
| Blumenkranz Mark S. |
|
– • – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
I/I |
66,131 |
1,276 |
|
- |
|
| Blumenkranz Mark S. |
|
– • – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,013 |
5,167 |
|
- |
|
| Blumenkranz Mark S. |
|
– • – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(70) |
779 |
|
- |
|
| Blumenkranz Mark S. |
|
– • – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(3) |
3,154 |
|
- |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2022-06-27 |
4 |
AS |
$0.37 |
$967 |
D/D |
(2,613) |
130,595 |
|
-71% |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2022-06-27 |
4 |
AS |
$0.37 |
$1,144 |
D/D |
(3,092) |
115,499 |
|
-71% |
|
| Brazzell Kim |
SEE REMARKS |
• – – |
2022-06-27 |
4 |
AS |
$0.37 |
$1,163 |
D/D |
(3,144) |
285,201 |
|
-71% |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2022-06-27 |
4 |
AS |
$0.37 |
$967 |
D/D |
(2,613) |
111,203 |
|
-71% |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-06-27 |
4 |
AS |
$0.37 |
$2,951 |
D/D |
(7,975) |
251,183 |
|
-71% |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2022-05-26 |
4 |
S |
$0.36 |
$365,667 |
I/I |
(1,005,686) |
7,039,613 |
|
22% |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2022-05-25 |
4 |
S |
$0.42 |
$602,494 |
I/I |
(1,434,509) |
8,045,299 |
|
39% |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2022-05-24 |
4 |
S |
$0.51 |
$73,851 |
I/I |
(144,805) |
9,479,808 |
|
50% |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2022-05-23 |
4 |
S |
$0.65 |
$812,500 |
I/I |
(1,250,000) |
9,624,613 |
|
63% |
|
144 Records found
|
|
Page 2 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.37 (5.19%) 
